Arrowhead Pharmaceuticals (ARWR) said Monday it has closed its licensing and collaboration agreement with Sarepta Therapeutics (SRPT), with Arrowhead getting a $500 million upfront payment and $325 million for the purchase by Sarepta of Arrowhead stock at $27.25 per share.
Arrowhead also said it will get $250 million to be paid in annual installments of $50 million over five years and may also get $300 million in near-term payments related to the enrollment of some groups of a phase 1/2 trial of ARO-DM1.
Additionally, Arrowhead said it may get development milestone payments of between $110 million and $410 million per program and sales milestone payments of between $500 million and $700 million per program as well as royalties on sales up to the low double digits.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.